4.4000
0.0000
(0.00%)
At close: January 29 at 3:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-17,612.0000
-17,612.0000
-24,126.0000
-35,718.0000
-18,254.0000
Investing Cash Flow
8,695.0000
8,695.0000
-7,999.0000
-30,262.0000
3,005.0000
Financing Cash Flow
4,050.0000
4,050.0000
6,417.0000
67,689.0000
58,200.0000
End Cash Position
14,556.0000
14,556.0000
19,237.0000
44,761.0000
43,154.0000
Capital Expenditure
-446.0000
-446.0000
-521.0000
-13,708.0000
--
Issuance of Capital Stock
5,094.0000
5,094.0000
7,111.0000
76,088.0000
58,334.0000
Issuance of Debt
--
--
--
--
500.0000
Repayment of Debt
-550.0000
-550.0000
-471.0000
-5,366.0000
--
Free Cash Flow
-18,058.0000
-18,058.0000
-24,647.0000
-49,426.0000
-18,254.0000
12/31/2020 - 11/23/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
8BT.F BriaCell Therapeutics Corp.
0.2760
-11.54%
BTTX Better Therapeutics, Inc.
0.0001
0.00%
NRXPW NRx Pharmaceuticals, Inc.
0.1490
-16.76%
GLPG.AS Galapagos NV
22.34
+0.72%
GLUE Monte Rosa Therapeutics, Inc.
6.45
+7.68%
RVNC Revance Therapeutics, Inc.
3.6300
-0.27%
HOPHF Hemogenyx Pharmaceuticals Plc
1.2400
0.00%
ZVRA Zevra Therapeutics, Inc.
8.02
+2.04%
TRAW Traws Pharma, Inc.
7.29
0.00%
RGNX REGENXBIO Inc.
7.90
+5.05%